Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -48,249 | -28,654 | -12,274 | -69,665 | -51,035 |
| Depreciation Amortization | 3,555 | 2,357 | 1,180 | 4,713 | 3,565 |
| Accounts payable and accrued liabilities | -1,236 | -2,372 | -1,940 | 257 | 403 |
| Other Working Capital | -9,370 | -11,277 | -7,808 | 10,409 | 8,403 |
| Other Operating Activity | 6,225 | 5,133 | 3,337 | 5,837 | 4,404 |
| Operating Cash Flow | $-49,075 | $-34,813 | $-17,505 | $-48,449 | $-34,260 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -759 | -731 | -695 | -1,100 | -1,054 |
| Investing Cash Flow | $-759 | $-731 | $-695 | $-1,100 | $-1,054 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 9 | 5 | 5 | 9 | 9 |
| Financing Cash Flow | $9 | $5 | $5 | $9 | $9 |
| Exchange Rate Effect | 4,325 | -869 | -1,022 | 7,741 | 2,105 |
| Beginning Cash Position | 131,572 | 131,572 | 131,572 | 173,371 | 173,371 |
| End Cash Position | 86,072 | 95,164 | 112,355 | 131,572 | 140,171 |
| Net Cash Flow | $-45,500 | $-36,408 | $-19,217 | $-41,799 | $-33,200 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,075 | -34,813 | -17,505 | -48,449 | -34,260 |
| Capital Expenditure | -759 | -731 | -695 | -1,100 | -1,054 |
| Free Cash Flow | -49,834 | -35,544 | -18,200 | -49,549 | -35,314 |